Form 4: Xenon Pharmaceuticals CEO Ian Mortimer Acquires Shares and Options
SEC Form 4 Filing
CEO Ian Mortimer reports acquisition of share options and restricted share units in Xenon Pharmaceuticals.
Summary
- Ian Mortimer, the President & CEO of Xenon Pharmaceuticals, reported changes in beneficial ownership.
- On March 12, 2025, Mortimer acquired 275,000 share options with an exercise price of $35.48, vesting 25% on March 12, 2026, and the remainder over the next three years.
- Mortimer also acquired 50,000 restricted share units, vesting 25% on each of the first four anniversaries of the grant date, starting March 12, 2026.
- Following these transactions, Mortimer directly owns 275,000 share options and 50,000 restricted share units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The CEO's acquisition of shares and options could be seen as a slightly positive signal, but it's not overtly bullish.
Positives
- The CEO's acquisition of share options and restricted share units could be interpreted as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules for the options and restricted share units suggest a multi-year commitment from the CEO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.
Stakeholder Impact
- The transactions could have a minor positive impact on shareholder sentiment, as they reflect the CEO's investment in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of transaction: Acquisition of share options and restricted share units. |
| 03/12/2026 | First vesting date for 25% of the share options and restricted share units. |
| 03/11/2035 | Expiration date of the share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.